ArkeaBio is developing a safe, user-friendly, and cost-conscious vaccine designed to reduce methane emissions from ruminant livestock and to integrate with existing global agribusiness practices. The company positions the vaccine as a scalable, low-cost tool to address agricultural methane, which the release cites as generating the equivalent of 3 billion tonnes of CO2 annually (about 6% of annual GHG emissions). ArkeaBio says its R&D results have attracted investor attention and that the vaccine is designed for rapid, on-farm implementation. The Series A proceeds will fund expansion of research and development, large-scale field trials, and engagement along the supply chain to support deployment. The company emphasizes collaborative work with industry partners, regulators, and environmental organizations to bring the product to market. Financially, ArkeaBio announced the close of a $26.5 million Series A financing to accelerate development and commercialization. ArkeaBio is a Boston, MI-based company developing an innovative vaccine to reduce methane emissions from ruminant animals, including cattle, sheep, and goats. Led by CEO Colin South, the company expects ruminant vaccinations to be a scalable and cost-effective solution to rapidly decarbonize global meat and dairy production. Its technology is intended to be integrated into proven delivery systems and existing farming practices to reduce methane emissions across multiple ruminant species, geographies, and agronomic systems. ArkeaBio intends to use newly raised funds to accelerate its research program. The company has stated it will position itself as a leader in the global effort to decarbonize the agricultural sector. No operating metrics were disclosed in the article.

Total raised

$39M

Funding rounds

2

Latest round

Series A

Latest activity

May 2024